Open-label, Two-part, Dose-escalation and Comparative Pharmacokinetics Study of UB-921 in Healthy Male Volunteers

Trial Profile

Open-label, Two-part, Dose-escalation and Comparative Pharmacokinetics Study of UB-921 in Healthy Male Volunteers

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 10 May 2017

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Sponsors United BioPharma
  • Most Recent Events

    • 03 May 2017 Planned initiation date changed from 1 Jun 2017 to 1 Jul 2017.
    • 16 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top